{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:12:47Z","timestamp":1782400367054,"version":"3.54.5"},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JADPRO"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:p>Objective: The 31-gene expression profile (31-GEP) can predict the risk of recurrence and metastasis in cutaneous melanoma (CM). We assessed the viewpoints and use of 31-GEP testing by physician assistants (PAs) and nurse practitioners (NPs) for patients with CM. Methods: NPs and PAs (n = 369) completed an 18-question online survey about their viewpoints and use of the 31-GEP risk-stratification test. Results: Most practitioners (n = 334, 90.5%) felt prognostic testing improved patient care and would recommend the 31-GEP to a colleague (n = 333, 90.2%) or a friend or family member (n = 289, 78.3%) who was diagnosed with CM. The 31-GEP test was used by 176 respondents in the preceding 12 months (53%). Among users of the 31-GEP test, 78% stated that the results would impact follow-up schedule and referral, 66% overall treatment decisions, 62% sentinel lymph node biopsy recommendations, and 50% surveillance imaging. In thin tumors (\u2033 1 mm), 82% of 31-GEP users and 44% of nonusers stated that the 31-GEP results would impact their treatment plan decisions. Conclusion: The 31-GEP test significantly impacts treatment plans in CM, particularly for thin and stage I melanomas. Importantly, even nonusers stated that 31-GEP test results would impact treatment plans as well as recommendations to a friend or family member.<\/jats:p>","DOI":"10.6004\/jadpro.2023.14.7.3","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T01:21:29Z","timestamp":1702171289000},"page":"586-596","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Utility of the 31-Gene Expression Profile Test on the Management of Cutaneous Melanoma by Nurse Practitioners and Physician Assistants"],"prefix":"10.6004","volume":"14","author":[{"given":"Renata","family":"Block, MMS, PA-C","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Patterson, MMS, PA-C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"J. Siegel, PhD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Martin, PhD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"P. Quick, PhD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Hunt, MSN, APRN, FNP-C, AOCNP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","published-online":{"date-parts":[[2023,11,1]]},"container-title":["Journal of the Advanced Practitioner in Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T01:21:33Z","timestamp":1702171293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.advancedpractitioner.com\/issues\/volume-14,-number-7-(novdec-2023)\/clinical-utility-of-the-31-gene-expression-profile-test-on-the-management-of-cutaneous-melanoma-by-nurse-practitioners-and-physician-assistants.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.6004\/jadpro.2023.14.7.3","relation":{},"ISSN":["2150-0878"],"issn-type":[{"value":"2150-0878","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}